Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection

Richardson, Mike; Mirchandani, Jyotika; Duong, Joseph H.; Grimaldo, Sammy; Kocieda, Virginia; Hendel, Houria; Khalili, Kamel; Zagury, Jean François; Rappaport, Jay

doi:10.1016/s0753-3322(02)00327-x

Cited by 53 publications

(34 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the Tat protein of 86 aa from a clade B lab-adapted HIV-1 virus (HTLV-IIIB strain, clone BH-10) isolated more than 20 years ago [164] is very well recognized by sera from African individuals infected with different virus clades, including clade C, which is responsible for more than half of new HIV-1 infections worldwide [165], with similar prevalence and epitope mapping titers of anti-Tat antibodies [120]. Similarly, Tat proteins from different viral clades are cross-recognized by sera from HIV-1 seropositive individuals [166,167], and macaques immunized with a clade B recombinant Tat protein develop anti-Tat antibodies cross-reacting with HIV-1 Tat peptides from B and C clades [142].…”

Section: The Choice Of Tat As Vaccine Relevant Antigenmentioning

confidence: 99%

HIV-1 Tat-Based Vaccines: An Overview and Perspectives in the Field of HIV/AIDS Vaccine Development

Caputo

Gavioli

Bellino

et al. 2009

International Reviews of Immunology

View full text Add to dashboard Cite

Section: The Choice Of Tat As Vaccine Relevant Antigenmentioning

confidence: 99%

HIV-1 Tat-Based Vaccines: An Overview and Perspectives in the Field of HIV/AIDS Vaccine Development

Caputo

Gavioli

Bellino

et al. 2009

International Reviews of Immunology

View full text Add to dashboard Cite

“…[5][6][7][8][9][10][11] Thus, the inclusion of Tat in preventive and therapeutic vaccines has been pursued by several groups showing promising results in nonhuman primates [12][13][14][15][16] and in phase I and II clinical trials. [16][17][18][19] However, the development of vaccines able to induce protective responses has to face some major challenges such as: i) the compliance requested for mass immunizations; ii) the induction of immune responses in mucosal tissues, which are the predominant sites of HIV acquisition; 20 and iii) the isotypes of antibodies elicited, which may influence the level of vaccine efficacy.…”

mentioning

confidence: 99%

Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide

Finessi

Nicoli

Gallerani

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The use of the Tat protein of HIV in vaccines against AIDS showed promising results in primate and human studies. To characterize the impact of the administration route on the induction of humoral responses at systemic and mucosal levels, we compared intradermal, intramuscular and mucosal immunizations with Tat and a Tat-derived peptide. Mice were immunized with the Tat protein by different routes and the titer and isotype of anti-Tat antibodies were assessed in serum and mucosal lavages. Intramuscular and intradermal administrations showed comparable immunogenicity, while the mucosal administration was unable to induce IgM in serum and IgG at mucosal sites but showed superior immunogenicity in terms of IgA induction. Anti-Tat antibodies were also obtained upon vaccination with the immunodominant Tat 1–20 peptide which was, however, less immunogenic than the whole Tat protein

show abstract

“…To analyze the specificity of antibodies, which may exert other effector functions, methods such as ELISA, immunoblotting, customized Luminex binding assays and microarrays are currently used ( table 1 ) [27,42,[45][46][47][48] . These assays are based on the recognition of Fc portions of antibodies present in human samples by labelled secondary antibodies (e.g.…”

Section: Analysis Of Isotypes Functions and Specificities Of Hiv-spementioning

confidence: 99%

“…They therefore allow determinations of antibody isotypes and IgG subclasses specific for the antigens used, which can be pro- teins, peptides and carbohydrates [42,[48][49][50] . Mapping the position of linear epitopes on the amino acid sequence of proteins is achieved with panels of synthetic overlapping peptides [46,48,[51][52][53] . However, testing the specificity of antibodies against a large number of peptides and proteins with assays such as ELISA is time-consuming and requires large amounts of the samples.…”

Section: Analysis Of Isotypes Functions and Specificities Of Hiv-spementioning

confidence: 99%

“…For example, it has been shown that p17, p24 and PR-specific antibodies were associated with nonprogression or a stable clinical status [45,144,145,152,160] . On the other hand, p31-specific antibodies were found to be associated with a worse prognosis, and results obtained for Tat-and Vprspecific responses were controversial ( table 7 ) [45,46,[146][147][148]155] . The use of antibody reactivity patterns as prognostic markers has not yet been established for the clinical practice.…”

Section: Igg Subclass Distribution Of Env-specific Antibodies During mentioning

confidence: 99%

See 1 more Smart Citation

HIV-Specific Antibody Responses in HIV-Infected Patients: From a Monoclonal to a Polyclonal View

Gallerano¹,

Cabauatan²,

Sibanda³

et al. 2015

Int Arch Allergy Immunol

View full text Add to dashboard Cite

HIV infections represent a major global health threat, affecting more than 35 million individuals worldwide. High infection rates and problems associated with lifelong antiretroviral treatment emphasize the need for the development of prophylactic and therapeutic immune intervention strategies. It is conceivable that insights for the design of new immunogens capable of eliciting protective immune responses may come from the analysis of HIV-specific antibody responses in infected patients. Using sophisticated technologies, several monoclonal neutralizing antibodies were isolated from HIV-infected individuals. However, the majority of polyclonal antibody responses found in infected patients are nonneutralizing. Comprehensive analyses of the molecular targets of HIV-specific antibody responses identified that during natural infection antibodies are mainly misdirected towards gp120 epitopes outside of the CD4-binding site and against regions and proteins that are not exposed on the surface of the virus. We therefore argue that vaccines aiming to induce protective responses should include engineered immunogens, which are capable of focusing the immune response towards protective epitopes.

show abstract

Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection

Cited by 53 publications

References 59 publications

HIV-1 Tat-Based Vaccines: An Overview and Perspectives in the Field of HIV/AIDS Vaccine Development

HIV-1 Tat-Based Vaccines: An Overview and Perspectives in the Field of HIV/AIDS Vaccine Development

Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide

HIV-Specific Antibody Responses in HIV-Infected Patients: From a Monoclonal to a Polyclonal View

Contact Info

Product

Resources

About